DelMar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DMPI)

$1.40 0.09 (6.87 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$1.40
Today's Range$1.31 - $1.43
52-Week Range$0.78 - $5.39
Volume230,178 shs
Average Volume1.48 million shs
Market Capitalization$30.24 million
P/E Ratio-2.06
Dividend YieldN/A
Beta1227.2

About DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Shell Companies
Sub-IndustryN/A
SectorFinancials
SymbolNASDAQ:DMPI
CUSIPN/A
Phone+1-604-6295989

Debt

Debt-to-Equity RatioN/A
Current Ratio9.48%
Quick Ratio9.48%

Price-To-Earnings

Trailing P/E Ratio-2.05882352941176
Forward P/E Ratio-2.59
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book140.00

Profitability

Trailing EPS($0.68)
Net Income$-8,080,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-119.62%

Miscellaneous

Employees15
Outstanding Shares21,600,000

DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split on the morning of Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. View DelMar Pharmaceuticals' Earnings History.

When will DelMar Pharmaceuticals make its next earnings announcement?

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for DelMar Pharmaceuticals.

Where is DelMar Pharmaceuticals' stock going? Where will DelMar Pharmaceuticals' stock price be in 2018?

3 analysts have issued twelve-month price targets for DelMar Pharmaceuticals' shares. Their forecasts range from $11.00 to $12.00. On average, they anticipate DelMar Pharmaceuticals' share price to reach $11.50 in the next year. View Analyst Ratings for DelMar Pharmaceuticals.

What are Wall Street analysts saying about DelMar Pharmaceuticals stock?

Here are some recent quotes from research analysts about DelMar Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "Ovarian Cancer Role for VAL-083; Reiterate Buy Stock Data 10/13/2017 Price $0.88 Exchange NASDAQ Price Target $12.00 52-Week High $5.77 52-Week Low $0.80 Enterprise Value (M) $12.4 Market Cap (M) $19 Public Market Float (M) 19.3 Shares Outstanding (M) 21.6 3 Month Avg Volume 959,521 Short Interest (M) 0.35 Balance Sheet Metrics Cash (M) $6.59 Total Debt (M) $0.00 Total Cash/Share $0.31 Book Value/Share $(0.09) EPS Diluted Full Year – Jun 2016A 2017A 2018E 1Q (0.15) (0.23) (0.17) 2Q (0.24) (0.13) (0.16) 3Q (0.10) (0.18) (0.14) 4Q (0.31) (0.20) (0.12) FY (0.81) (0.74) (0.57) 6 5 4 3 2 1 0 OCT- 16 FEB- 17 J UN- 17 OCT- 17 40 30 20 10 0 Vol. (mil) Price Continuing coverage under the name H.C. Wainwright & Co. with a Buy rating. Effective October 5, 2017, research in the above titled name will now be published under H.C. Wainwright & Co. and no longer distributed in conjunction with ‘Rodman & Renshaw, a unit of H.C." (10/16/2017)
  • 2. Maxim Group analysts commented, "Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins." (9/11/2017)

Who are some of DelMar Pharmaceuticals' key competitors?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:

  • Erich Mohr Ph.D., Chairman of the Board (Age 62)
  • Saiid Zarrabian, Interim President, Interim Chief Executive Officer, Director (Age 64)
  • Scott Praill, Chief Financial Officer (Age 50)
  • Dennis M. Brown Ph.D., Chief Scientific Officer, Director (Age 66)
  • John K. Bell, Lead Independent Director (Age 68)
  • Jeffrey A. Bacha, Director (Age 48)
  • Lynda Sarah Cranston, Independent Director (Age 68)
  • Robert J. Toth Jr., Independent Director (Age 53)

How do I buy DelMar Pharmaceuticals stock?

Shares of DelMar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DelMar Pharmaceuticals stock can currently be purchased for approximately $1.40.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $30.24 million. The company earns $-8,080,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. DelMar Pharmaceuticals employs 15 workers across the globe.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-604-6295989 or via email at [email protected]


MarketBeat Community Rating for DelMar Pharmaceuticals (DMPI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DelMar Pharmaceuticals (NASDAQ:DMPI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.752.753.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$13.00$13.00$13.00
Price Target Upside: 709.86% upside1,297.85% upside1,384.02% upside488.24% upside

DelMar Pharmaceuticals (NASDAQ:DMPI) Consensus Price Target History

Price Target History for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ:DMPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018HC WainwrightSet Price TargetBuy$12.00MediumView Rating Details
9/11/2017Maxim GroupReiterated RatingHoldHighView Rating Details
8/8/2017Dawson JamesReiterated RatingBuyHighView Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00N/AView Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

DelMar Pharmaceuticals (NASDAQ:DMPI) Earnings History and Estimates Chart

Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ DMPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.16)N/AView Earnings Details
11/13/2017($0.17)($0.18)ViewN/AView Earnings Details
9/27/2017Q4 2017($0.19)($0.20)ViewN/AView Earnings Details
5/18/2017($0.18)($0.18)ViewN/AView Earnings Details
2/10/201712/31/2016($0.22)($0.13)ViewN/AView Earnings Details
11/10/20169/30/2016($0.15)($0.23)ViewN/AView Earnings Details
9/13/2016Q4 2016($0.17)($0.17)ViewN/AView Earnings Details
5/12/2016Q3 2016($0.16)($0.12)ViewN/AView Earnings Details
2/16/2016Q2 16($0.03)($0.06)ViewN/AView Earnings Details
11/16/2015Q1 2016($0.12)($0.16)ViewN/AView Earnings Details
9/4/2015Q4 2015($0.09)($0.02)ViewN/AView Earnings Details
5/15/2015Q3 2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015Q2 2015($0.06)($0.03)ViewN/AView Earnings Details
11/10/2014Q1 2015($0.07)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

DelMar Pharmaceuticals (NASDAQ:DMPI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS

Dividends

Dividend History for DelMar Pharmaceuticals (NASDAQ:DMPI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

DelMar Pharmaceuticals (NASDAQ DMPI) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 16.91%
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals (NASDAQ DMPI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017John K BellDirectorBuy20,000$0.81$16,200.00View SEC Filing  
11/14/2017Saiid ZarrabianCEOBuy60,900$0.82$49,938.00View SEC Filing  
10/6/2017Jeffrey BachaCEOBuy10,000$0.87$8,700.00View SEC Filing  
10/5/2017Scott PraillInsiderBuy17,500$0.85$14,875.00View SEC Filing  
6/26/2017Jeffrey BachaCEOBuy6,700$3.60$24,120.0053,345View SEC Filing  
6/26/2017John K BellDirectorBuy4,167$3.60$15,001.20View SEC Filing  
6/6/2017Jeffrey BachaCEOBuy5,000$2.12$10,600.0046,645View SEC Filing  
6/6/2017John K BellDirectorBuy10,000$2.12$21,200.00View SEC Filing  
6/6/2017Scott PraillCFOBuy9,500$2.10$19,950.0025,277View SEC Filing  
5/5/2017Jeffrey BachaCEOBuy2,500$2.20$5,500.0041,645View SEC Filing  
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.0038,969View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00137,985View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00130,485View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00127,485View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

DelMar Pharmaceuticals (NASDAQ DMPI) News Headlines

Source:
DateHeadline
 DelMar Pharmaceuticals Inc (DMPI) Receives Average Rating of "Buy" from Brokerages DelMar Pharmaceuticals Inc (DMPI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 19 at 9:32 AM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Rating of "Buy" by BrokeragesZacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 5:08 PM
Zacks: DelMar Pharmaceuticals Inc (DMPI) Receives Consensus Rating of "Buy" from AnalystsZacks: DelMar Pharmaceuticals Inc (DMPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 11:16 PM
DelMar Pharmaceuticals stock rockets after cancer treatment granted Fast Track designation - MarketWatchDelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation - MarketWatch
www.marketwatch.com - December 28 at 8:18 AM
A Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - BenzingaA Peek Into The Markets: US Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals - Benzinga
www.benzinga.com - December 26 at 9:06 AM
Delmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.comDelmar Pharma (DMPI) Gramted Fast Track Designation for VAL ... - StreetInsider.com
www.streetinsider.com - December 26 at 9:06 AM
DelMar Pharmaceuticals stock rockets after cancer treatment granted Fast Track designationDelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation
finance.yahoo.com - December 26 at 9:06 AM
 DelMar Pharmaceuticals, Inc. (DMPI) Receives Consensus Rating of "Buy" from Analysts DelMar Pharmaceuticals, Inc. (DMPI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 22 at 12:20 AM
Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?
finance.yahoo.com - December 8 at 5:04 PM
 DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of "Buy" by Analysts DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 6 at 2:46 PM
Contrasting DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)Contrasting DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)
www.americanbankingnews.com - November 30 at 11:24 PM
 Analysts Anticipate DelMar Pharmaceuticals, Inc. (DMPI) Will Post Earnings of -$0.16 Per Share Analysts Anticipate DelMar Pharmaceuticals, Inc. (DMPI) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - November 30 at 1:26 AM
DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI) Financial ComparisonDelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI) Financial Comparison
www.americanbankingnews.com - November 29 at 9:44 PM
HC Wainwright Analysts Give DelMar Pharmaceuticals (DMPI) a $12.00 Price TargetHC Wainwright Analysts Give DelMar Pharmaceuticals (DMPI) a $12.00 Price Target
www.americanbankingnews.com - November 29 at 7:30 PM
Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI) Critical ContrastJavelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI) Critical Contrast
www.americanbankingnews.com - November 27 at 1:38 AM
Reviewing Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI)Reviewing Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 26 at 1:16 AM
Financial Survey: DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)Financial Survey: DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI)
www.americanbankingnews.com - November 25 at 5:10 PM
Comparing Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)Comparing Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 24 at 5:36 AM
Zacks: DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by BrokeragesZacks: DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by Brokerages
www.americanbankingnews.com - November 21 at 11:28 PM
Delmar Pharma (DMPI) Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM ... - StreetInsider.comDelmar Pharma (DMPI) Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM ... - StreetInsider.com
www.streetinsider.com - November 21 at 6:12 PM
DelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI) Head to Head ReviewDelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI) Head to Head Review
www.americanbankingnews.com - November 21 at 5:23 PM
Head to Head Review: Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)Head to Head Review: Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 21 at 5:38 AM
Comparing Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)Comparing Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 19 at 7:12 PM
 DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by Brokerages DelMar Pharmaceuticals, Inc. (DMPI) Given $11.16 Consensus Target Price by Brokerages
www.americanbankingnews.com - November 18 at 9:16 AM
DelMar Pharmaceuticals (DMPI) vs. Javelin Mortgage Investment Corp (JMI) Critical ReviewDelMar Pharmaceuticals (DMPI) vs. Javelin Mortgage Investment Corp (JMI) Critical Review
www.americanbankingnews.com - November 18 at 8:24 AM
DelMar Pharmaceuticals, Inc. (DMPI) Director Purchases $16,200.00 in StockDelMar Pharmaceuticals, Inc. (DMPI) Director Purchases $16,200.00 in Stock
www.americanbankingnews.com - November 17 at 9:50 PM
Insider Buying: DelMar Pharmaceuticals, Inc. (DMPI) CEO Acquires 60,900 Shares of StockInsider Buying: DelMar Pharmaceuticals, Inc. (DMPI) CEO Acquires 60,900 Shares of Stock
www.americanbankingnews.com - November 16 at 9:25 PM
Critical Survey: Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)Critical Survey: Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 16 at 3:12 AM
Critical Review: Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)Critical Review: Javelin Mortgage Investment Corp (JMI) and DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 15 at 7:32 PM
Reviewing DelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI)Reviewing DelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI)
www.americanbankingnews.com - November 15 at 3:30 PM
DelMar Pharmaceuticals, Inc. (DMPI) Issues Quarterly  Earnings ResultsDelMar Pharmaceuticals, Inc. (DMPI) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 14 at 4:28 PM
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial ResultsDelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
finance.yahoo.com - November 13 at 6:36 PM
Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI) Head-To-Head AnalysisJavelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI) Head-To-Head Analysis
www.americanbankingnews.com - November 12 at 9:52 AM
-$0.16 EPS Expected for DelMar Pharmaceuticals, Inc. (DMPI) This Quarter-$0.16 EPS Expected for DelMar Pharmaceuticals, Inc. (DMPI) This Quarter
www.americanbankingnews.com - November 11 at 11:12 AM
Critical Survey: Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)Critical Survey: Javelin Mortgage Investment Corp (JMI) & DelMar Pharmaceuticals (DMPI)
www.americanbankingnews.com - November 10 at 11:30 PM
DelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI) Critical ComparisonDelMar Pharmaceuticals (DMPI) & Javelin Mortgage Investment Corp (JMI) Critical Comparison
www.americanbankingnews.com - November 7 at 5:34 AM
Delmar Pharma (DMPI) Presents Data Supporting VAL-083 ... - StreetInsider.comDelmar Pharma (DMPI) Presents Data Supporting VAL-083 ... - StreetInsider.com
www.streetinsider.com - November 2 at 5:00 AM
Delmar Pharma (DMPI) Presents Data Supporting VAL-083 Combination for Treatment of Solid Tumors including Brain and Ovarian CancerDelmar Pharma (DMPI) Presents Data Supporting VAL-083 Combination for Treatment of Solid Tumors including Brain and Ovarian Cancer
www.streetinsider.com - October 31 at 7:08 PM
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian CancerDelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer
finance.yahoo.com - October 31 at 7:08 PM
ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM TumorsONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors
finance.yahoo.com - October 24 at 8:30 PM
DelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.17 Per ShareDelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - October 22 at 2:06 PM
Is Now The Right Time To Invest In Healthcare And DelMar Pharmaceuticals Inc (DMPI)?Is Now The Right Time To Invest In Healthcare And DelMar Pharmaceuticals Inc (DMPI)?
finance.yahoo.com - October 17 at 6:44 PM
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)
finance.yahoo.com - October 10 at 3:40 PM
DelMar Pharmaceuticals, Inc. (DMPI) Insider Buys $14,875.00 in StockDelMar Pharmaceuticals, Inc. (DMPI) Insider Buys $14,875.00 in Stock
www.americanbankingnews.com - October 5 at 10:28 PM
HC Wainwright Reaffirms Buy Rating for DelMar Pharmaceuticals, Inc. (DMPI)HC Wainwright Reaffirms Buy Rating for DelMar Pharmaceuticals, Inc. (DMPI)
www.americanbankingnews.com - October 5 at 3:38 PM
Earnings Review and Free Research Report: DelMar Missed Earnings ExpectationsEarnings Review and Free Research Report: DelMar Missed Earnings Expectations
finance.yahoo.com - October 5 at 10:16 AM
Investor Network: DelMar Pharmaceuticals, Inc. to Host Earnings CallInvestor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - October 4 at 4:40 PM
DelMar Pharmaceuticals Presents Poster at AACRs Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian CancerDelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
finance.yahoo.com - October 3 at 8:49 AM
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-MarketDelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market
finance.yahoo.com - September 22 at 4:59 PM
Todays Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis PharmaceuticalsToday's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals
finance.yahoo.com - September 21 at 9:24 AM

SEC Filings

DelMar Pharmaceuticals (NASDAQ:DMPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

DelMar Pharmaceuticals (NASDAQ DMPI) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.